Stay updated with breaking news from Marca Pfeffer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recent guidelines have restricted aspirin use in the primary prevention of cardiovascular disease to patients under 70, and more recent guidance to patients under 60. Yet, the risks of heart attacks and strokes increase markedly with age.
Sacubitril-valsartan is not associated with a reduced incidence of death from CV causes or incident heart failure compared with ramipril.
May 15, 2021 For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI trial shows. sacubitril/valsartan is superior to an ACE inhibitor in patients who have symptomatic HF with reduced ejection fraction when it comes to reducing both HF events and total mortality, PARADISE-MI fell short by missing its primary endpoint of a 15% reduction in events needed to demonstrate superiority of the angiotensin receptor neprilysin inhibitor (ARNI) over an ACE inhibit...